Koninklijke Philips (PHG) Net Income towards Common Stockholders (2009 - 2026)
Koninklijke Philips' (PHG) quarterly Net Income towards Common Stockholders came in at $176.8 million in Q1 2026, up 121.14% year-on-year from $79.9 million in Q1 2025, and down 61.55% quarter-over-quarter from $459.8 million in Q4 2025.
Koninklijke Philips (PHG) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Koninklijke Philips' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $176.8 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 121.14% year-over-year to $176.8 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 678.04% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 238.88% from the prior year.
- Net Income towards Common Stockholders slipped to $176.8 million in Q1 2026 per PHG's latest filing, from $459.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $485.7 million in Q2 2024 and bottomed at -$1.5 billion in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is -$188.9 million (2022), against an average of -$266.9 million.
- Across the five-year window, Net Income towards Common Stockholders tumbled 522875.37% in 2022 and soared 228.83% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$115.3 million in 2022, then tumbled by 325.57% to -$490.6 million in 2023, then grew by 27.25% to -$356.9 million in 2024, then surged by 228.83% to $459.8 million in 2025, then tumbled by 61.55% to $176.8 million in 2026.
- Per Business Quant, the three latest PHG Net Income towards Common Stockholders figures stand at $176.8 million (Q1 2026), $459.8 million (Q4 2025), and $215.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.59 Bn | 176.29 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 129.07 Bn | 126.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.58 Bn | 99.36 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.64 Bn | 67.19 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.38 Bn | 44.71 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.13 Bn | 25.84 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.27 Bn | 21.15 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Steris | 21.43 Bn | 20.99 Bn | 697.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.78 Mn |
| Dec 31, 2025 | 459.80 Mn |
| Sep 30, 2025 | 215.11 Mn |
| Jun 30, 2025 | 271.67 Mn |
| Mar 31, 2025 | 79.94 Mn |
| Dec 31, 2024 | -356.91 Mn |
| Sep 30, 2024 | -403.05 Mn |
| Jun 30, 2024 | 485.68 Mn |
| Mar 31, 2024 | -1.09 Bn |
| Dec 31, 2023 | -490.63 Mn |
| Sep 30, 2023 | -538.85 Mn |
| Jun 30, 2023 | -643.55 Mn |
| Mar 31, 2023 | -711.63 Mn |
| Dec 31, 2022 | -115.29 Mn |
| Sep 30, 2022 | -1.52 Bn |
| Jun 30, 2022 | -188.87 Mn |
| Mar 31, 2022 | -170.60 Mn |
| Dec 31, 2021 | 165.88 Mn |
| Sep 30, 2021 | 566,057.91 |
| Jun 30, 2021 | 36,128.14 |